Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM128618, GM128618)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK126855, DK110559, DK126855)
Article History
Received: 23 December 2022
Accepted: 8 December 2023
First Online: 12 February 2024
Competing interests
: A.S.D. is an ad hoc consultant for Takeda Pharmaceuticals, Axial Therapeutics and Ferring Pharmaceuticals. S.N.C. is an ad hoc consultant for Metis Therapeutics. G.D.D’A. declares no competing interests.